Development of antibody-targeted vaccines

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 2, 2005, Pages 157-163

  Keler, Tibor ^a   He, LiZhen ^a   Graziano, Robert F ^a  

^a MEDAREX INC   (United States)

Author keywords

Antigen presentation; Dendritic cells; Monoclonal antibodies; Targeted vaccines

Indexed keywords

ANTIBODY TARGETED VACCINE; ANTIGEN; ANTIINFECTIVE AGENT; AUTOANTIGEN; AVIDIN; CHORIONIC GONADOTROPIN ANTIBODY; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOTOXIC AGENT; DINITROPHENYLHAPTEN; FC RECEPTOR; FERRITIN; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; OVALBUMIN; PILIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN A; TETANUS TOXOID; THYROGLOBULIN; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS GLYCOPROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER; CANCER CELL; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG TARGETING; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN BINDING; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; VIRUS TITRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; HUMANS; VACCINES;

EID: 17144392160     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Kovacsovics-Bankowski M, Rock KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 267(5195):243-246.
2. Ackerman AL, Kyritsis C, Tempe R, Cresswell P: Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat Immunol (2005) 6 1):107-113.
3. Lanzavecchia A: Mechanisms of antigen uptake for presentation. Curr Opin Immunol (1996) 8(3):348-354.
4. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F, MacDonald HR: In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T-cell responses. J Clin Invest (2003) 111(11):1673-1681.
5. Parmiani G, Testori A, Maio M, Castelli C, Rivoltini L, Pilla L, Belli F, Mazzaferro V, Coppa J, Patuzzo R, Sertoli MR et al: Heat shock proteins and their use as anticancer vaccines. Clin Cancer Res (2004) 10(24):8142-8146.
6. Kalergis AM, Ravetch JV: Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J Exp Med (2002) 195(12):1653-1659.
7. Rafiq K, Bergtold A, Clynes R: Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest (2002) 110(1):71-79.
8. Kim SJ, Suh D, Park SE, Park JS, Byun HM, Lee C, Lee SY, Kim I, Oh YK: Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES. Virology (2003) 314(1):84-91.
9. Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, Baskar S, Wang JM, Kwak LW: Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood (2004) 104(7):1961-1969.
10. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S: Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 189(2):371-380.
11. Nagata Y, Ono S, Matsuo M, Gnjatic S, Valmori D, Ritter G, Garrett W, Old LJ, Mellman I: Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA (2002) 99 16):10629-10634.
12. Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol (2001) 19:275-290.
13. Tony HP, Parker DC: Major histocompatibility complex-restricted, polyclonal B cell responses resulting from helper T-cell recognition of antiimmunoglobulin presented by small B lymphocytes. J Exp Med (1985) 161(1):223-241.
14. Chesnut RW, Grey HM: Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol (1981) 126 3):1075-1079.
15. Heijnen IA, van Vugt MJ, Fanger NA, Graziano RF, de Wit TP, Hofhuis FM, Guyre PM, Capel PJ, Verbeek JS, van de Winkel JG: Antigen targeting to myeloid-specific human Fcγ RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest (1996) 97(2):331-338.
16. Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van De Winkel JG, Deo YM, Graziano RF: Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol (2000) 165(12):6738-6742.
17. Lunde E, Munthe LA, Vabo A, Sandlie I, Bogen B: Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat Biotechnol (1999) 17(7):670-675.
18. Lunde E, Western KH, Rasmussen IB, Sandlie I, Bogen B: Efficient delivery of T-cell epitopes to APC by use of MHC class II-specific Troybodies. J Immunol (2002) 168(5):2154-2162.
19. Zaghouani H, Steinman R, Nonacs R, Shah H, Gerhard W, Bona C: Presentation of a viral T-cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science (1993) 259 5092):224-227.
20. Kriangkum J, Xu B, Nagata LP, Fulton RE, Suresh MR: Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng (2001) 18(2):31-40.
21. Holliger P, Prospero T, Winter G: "Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA (1993) 90(14):6444-6448.
22. Fenger MW, Morganelli PM, Guyre PM: Bispecific antibodies. Crit Rev Immunol (1992) 12(3-4):101-124.
23. Snider DP, Segal DM: Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, Fcγ RII, and B220 molecules on murine splenic B cells. J Immunol (1989) 143 1):59-65.
24. Snider DP, Kaubisch A, Segal DM: Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med (1990) 171(6):1957-1963.
25. Snider DP, Segal DM: Targeted antigen presentation using crosslinked antibody heteroaggregates. J Immunol (1987) 139 5):1609-1616.
26. Hudson PJ, Souriau C: Engineered antibodies. Nat Med (2003) 9(1):129-134.
27. Liu C, Goldstein J, Graziano RF, He J, O'Shea JK, Deo Y, Guyre PM: FcγRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T-cell epitopes. J Clin Invest (1996) 98(9):2001-2007.
28. Walsh MC, Banas JA, Mudzinski SP, Preissler MT, Graziano RF, Gosselin EJ: A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcγRI-streptavidin construct and microspheres coated with biotinylated-antigen. Biomol Eng (2003) 20(1):21-33.
29. Serre K, Machy P, Grivel JC, Jolly G, Brun N, Barbet J, Leserman L: Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. J Immunol (1998) 161 11):6059-6067.
30. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG: Targeting dendritic cells with antigen-containing liposomes: A highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res (2004) 64(12):4357-4365.
31. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA (1993) 90(8):3539-3543.
32. Skea DL, Barber BH: Studies of the adjuvant-independent antibody response to immunotargeting. Target structure dependence, isotype distribution, and induction of long term memory. J Immunol (1993) 151(7):3557-3568.
33. Carayanniotis G, Skea DL, Luscher MA, Barber BH: Adjuvant-independent immunization by immunotargeting antigens to MHC and non-MHC determinants in vivo. Mol Immunol (1991) 28 3):261-267.
34. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM: In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T-cell vaccination. J Exp Med (2004) 199 6):815-824.
35. He LZ, Ramakrishna V, Connolly JE, Wang XT, Smith PA, Jones CL, Valkova-Valchanova M, Arunakumari A, Treml JF, Goldstein J, Wallace PK et al: A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin β. Clin Cancer Res (2004) 10(6):1920-1927.
36. Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, Keler T, Endres MJ: Mannose receptor targeting of tumor antigen pmeI17 to human dendritic cells directs anti-melanoma T-cell responses via multiple HLA molecules. J Immunol (2004) 172(5):2845-2852.
37. Carayanniotis G, Barber BH: Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature (1987) 327(6117):59-61.
38. Wu JY, Taylor RK, Wade WF: Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: Modulation of serologic response, epitope specificity, and isotype. Infect Immun (2001) 69(12):7679-7686.
39. Barr TA, McCormick AL, Carlring J, Heath AW: A potent adjuvant effect of CD40 antibody attached to antigen. Immunology (2003) 109(1):87-92.
40. Balasa B, Carayanniotis G: Immunotargeting of thyroglobulin on antigen presenting cells abrogates natural tolerance in the absence of adjuvant. Cell Immunol (1993) 150 2):453-458.
41. Wang H, Griffiths MN, Burton DR, Ghazal P: Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA (2000) 97(2):847-852.
42. Berry JD, Licea A, Popkov M, Cortez X, Fuller R, Elia M, Kerwin L, Kubitz D, Barbas CF 3rd: Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybrid Hybridomics (2003) 22(1):23-31.
43. Snider DP, Underdown BJ, McDermott MR: Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice. Immunology (1997) 90 3):323-329.
44. Kawamura H, Berzofsky JA: Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J Immunol (1986) 136(1):58-65.
45. Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre PM: Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens. J Immunol (1992) 149(11):3477-3481.
46. Fanger NA, Voigtlaender D, Liu C, Swink S, Wardwell K, Fisher J, Graziano RF, Pfefferkorn LC, Guyre PM: Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fcγ RI (CD64) expressed on human blood dendritic cells. J Immunol (1997) 158(7):3090-3098.
47. Schjetne KW, Gundersen HT, Iversen JG, Thompson KM, Bogen B: Antibody-mediated delivery of antigen to chemokine receptors on antigen-presenting cells results in enhanced CD4+ T-cell responses. Eur J Immunol (2003) 33(11):3101-3108.
48. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC: Dendritic cells induce peripheral T-cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 194(6):769-779.
49. Mellman I, Steinman RM: Dendritic cells: Specialized and regulated antigen processing machines. Cell (2001) 106 3):255-258.
50. Wallace PK, Tsang KY, Goldstein J, Correale P, Jarry TM, Schlom J, Guyre PM, Ernstoff MS, Fanger MW: Exogenous antigen targeted to FcγRI on myeloid cells is presented in association with MHC class I. J Immunol Methods (2001) 248(1-2):183-194.
51. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM: Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T-cell tolerance. J Exp Med (2002) 196(12):1627-1638.
52. Guo M, Gong S, Maric S, Misulovin Z, Pack M, Mahnke K, Nussenzweig MC, Steinman RM: A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol (2000) 61(8):729-738.
53. Heath WR, Carbone FR: Cross-presentation, dendritic cells, tolerance and immunity. Ann Rev Immunol (2001) 19:47-64.
54. Rasmussen IB, Lunde E, Michaelsen TE, Bogen B, Sandlie I: The principle of delivery of T-cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: Implications for peptide vaccination. Proc Natl Acad Sci USA (2001) 98(18):10296-10301.
55. Frleta D, Demian D, Wade WF: Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo. Int Immunopharmacol (2001) 1(2):265-275.
56. Carayanniotis G, Barber BH: Characterization of the adjuvant-free serological response to protein antigens coupled to antibodies specific for class II MHC determinants. Vaccine (1990) 8(2):137-144.
57. Baiu DC, Prechl J, Tchorbanov A, Molina HD, Erdei A, Sulica A, Capel PJ, Hazenbos WL: Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors. J Immunol (1999) 162(6):3125-3130.